| Dec'19 | Dec'18 | Dec'17 | Dec'16 | Dec'15 | Dec'14 | Dec'13 | Dec'12 | Dec'11 | Dec'10 | Dec'09 |
|---|---|---|---|---|---|---|---|---|---|---|
Operating activities: | ||||||||||
Net loss | ||||||||||
-84,486 | -126,757 | -53,481 | -66,745 | -75,096 | -73,673 | -39,796 | -38,444 | -28,546 | -29,251 | -21,089 |
Adjustments to reconcile net loss to net cash used in operating activities: | ||||||||||
Stock-based compensation expense | ||||||||||
13,785 | 11,713 | 12,688 | 13,582 | 9,581 | 8,918 | 6,252 | 4,281 | 1,927 | 2,178 | 1,494 |
Non-cash interest expense | ||||||||||
9,232 | 5,635 | 4,187 | 1,977 | 1,045 | 738 | 502 | 354 | 352 | 174 | 253 |
Change in fair value of preferred stock warrant values and success fee liability | ||||||||||
- | - | - | - | - | - | - | - | - | - | 848 |
Gain on sale of assets | ||||||||||
- | - | - | - | - | - | - | 0 | - | - | - |
Depreciation and amortization | ||||||||||
1,800 | 1,000 | 551 | 300 | 209 | 317 | 302 | 320 | 435 | 472 | 451 |
Loss on early extinguishment of debt | ||||||||||
- | -12,993 | 0 | -5,595 | -1,315 | 0 | 0 | - | - | -296 | - |
Deferred income tax | ||||||||||
0 | -12,929 | 0 | 0 | - | - | - | - | - | - | - |
Fair value adjustment to convertible notes in equity | ||||||||||
- | 354 | 0 | 0 | - | - | - | - | - | - | - |
Warrant modification expense | ||||||||||
- | - | - | - | - | 863 | 41 | 511 | 0 | 33 | -34 |
Changes in operating assets and liabilities: | ||||||||||
Receivables | ||||||||||
12,367 | 5,674 | 5,107 | 5,520 | 6,125 | 13 | -1,555 | 1,059 | -2,254 | 1,231 | 41 |
Inventory | ||||||||||
1,059 | -355 | -685 | 656 | -96 | 568 | 0 | 0 | - | - | - |
Prepaid expenses and other assets | ||||||||||
251 | 498 | 5,270 | -347 | 586 | 987 | -84 | 438 | 201 | 87 | -42 |
Accounts payable and accrued expenses | ||||||||||
13,283 | 10,109 | 9,616 | -421 | 4,352 | 5,459 | -1,169 | -2 | 339 | 1,462 | 207 |
Deferred revenue | ||||||||||
- | - | - | - | - | - | -970 | -4,718 | -2,228 | 11,452 | 470 |
Deferred rent | ||||||||||
- | - | -96 | 37 | - | 902 | 3,504 | 4,644 | 0 | - | - |
Net cash used in operating activities | ||||||||||
-60,100 | -103,700 | -36,227 | -51,504 | -65,209 | -58,044 | -29,695 | -34,551 | -25,668 | -14,502 | -19,027 |
Investing activities: | ||||||||||
Purchases of property and equipment | ||||||||||
334 | 567 | 350 | 126 | 240 | 28 | 204 | 642 | 1,241 | 807 | 279 |
Purchases of investments | ||||||||||
58,217 | 68,782 | 65,326 | 73,966 | 91,766 | 58,849 | 47,182 | 49,547 | 9,000 | 57,765 | 64,207 |
Proceeds from the sale and maturities of investments | ||||||||||
55,150 | 94,500 | 28,078 | 57,757 | 71,400 | 65,034 | 55,295 | 49,282 | 27,150 | 78,173 | 11,045 |
Purchase of Patobios intellectual property assets | ||||||||||
- | - | - | - | - | - | - | - | - | 7,631 | - |
Reimbursement of Patobios intellectual property assets | ||||||||||
- | - | - | - | - | - | - | - | - | 7,631 | - |
Proceeds from the maturities of investments | ||||||||||
- | - | - | - | - | - | - | - | - | 323 | 1,039 |
Net cash provided by investing activities | ||||||||||
-3,401 | 25,151 | -37,598 | -16,335 | -20,606 | 6,157 | 7,909 | -907 | 16,909 | 19,924 | -52,402 |
Financing activities: | ||||||||||
Proceeds from issuance of convertible senior notes | ||||||||||
- | 210,000 | 0 | 0 | - | - | - | - | - | - | - |
Proceeds from debt borrowings | ||||||||||
- | 44,550 | - | - | - | - | - | - | - | - | - |
Proceeds from Issuance of Debt | ||||||||||
- | - | 0 | 100,000 | 50,000 | 32,000 | 0 | 6,492 | 9,942 | 9,742 | - |
Proceeds from issuance of common stock, net | ||||||||||
54,238 | - | 63,657 | 38,039 | 79,076 | 37,754 | 20,988 | 32,306 | 0 | - | 61,812 |
Proceeds upon exercise of stock options and warrants | ||||||||||
7,598 | 6,732 | 11,769 | 3,153 | 2,859 | 1,868 | 662 | 369 | 595 | 299 | 28 |
Release in restricted investments | ||||||||||
- | -4,681 | 0 | -4,844 | 10,000 | 0 | 0 | - | - | - | - |
Repayment of debt | ||||||||||
- | 132,077 | 0 | 70,137 | 32,000 | 20,000 | 0 | 6,194 | 1,051 | 13,005 | 4,120 |
Premium paid for capped call option | ||||||||||
- | 33,180 | 0 | 0 | - | - | - | - | - | - | - |
Payments on debt prepayment and extinguishment | ||||||||||
- | 11,902 | 0 | 5,700 | 2,673 | 521 | - | - | - | - | - |
Payments for debt issuance costs | ||||||||||
- | 6,800 | 0 | 1,501 | 436 | 244 | - | - | - | - | - |
Principal payments on finance lease liabilities | ||||||||||
1,139 | 951 | 431 | - | - | - | - | - | - | - | - |
Proceeds from issuance of convertible preferred stock, net of issuance costs | ||||||||||
- | - | - | - | - | - | - | - | - | - | 1,851 |
Other, net | ||||||||||
- | - | - | - | - | - | - | - | - | - | -48 |
Net cash provided by (used in) financing activities | ||||||||||
60,697 | 81,053 | 74,995 | 68,698 | 86,826 | 50,857 | 21,650 | 32,973 | 9,486 | -2,964 | 59,523 |
Net increase (decrease) in cash and cash equivalents | ||||||||||
-2,777 | 2,467 | 1,170 | 859 | 1,011 | -1,030 | -136 | -2,485 | 727 | 2,458 | -11,906 |
Supplemental cash flow information | ||||||||||
Cash paid for interest | ||||||||||
13,462 | 8,896 | 6,895 | 5,293 | 4,236 | 2,674 | 1,709 | 1,502 | 1,461 | 1,362 | 1,947 |
Issuance of warrants in connection with amendments to notes payable | ||||||||||
- | - | 0 | 758 | 0 | 0 | - | - | - | - | - |
Issuance of common stock to Patobios in connection with purchase of intellectual property assets | ||||||||||
- | - | - | - | - | - | - | - | - | 3,146 | - |
Reduction of equipment cost basis due to assets purchased with grant funding | ||||||||||
- | - | - | - | - | - | 0 | 67 | 1,689 | - | - |
Issuance of warrants in connection with the Vulcan funding agreement | ||||||||||
- | - | - | - | - | - | - | - | - | 994 | - |
Property acquired under finance lease | ||||||||||
1,440 | 2,118 | 1,141 | 404 | 137 | 200 | 0 | 30 | 0 | 201 | - |
Conversion of accrued interest to debt | ||||||||||
- | 3,408 | 3,315 | 516 | 0 | 0 | - | - | - | - | - |
Fair value of warrants issued in connection with debt amendment | ||||||||||
- | 1,424 | - | - | - | - | - | - | - | - | - |